JP2011503094A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503094A5
JP2011503094A5 JP2010533241A JP2010533241A JP2011503094A5 JP 2011503094 A5 JP2011503094 A5 JP 2011503094A5 JP 2010533241 A JP2010533241 A JP 2010533241A JP 2010533241 A JP2010533241 A JP 2010533241A JP 2011503094 A5 JP2011503094 A5 JP 2011503094A5
Authority
JP
Japan
Prior art keywords
antibody
factor
composition
fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010533241A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503094A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/082621 external-priority patent/WO2009061910A1/en
Publication of JP2011503094A publication Critical patent/JP2011503094A/ja
Publication of JP2011503094A5 publication Critical patent/JP2011503094A5/ja
Pending legal-status Critical Current

Links

JP2010533241A 2007-11-08 2008-11-06 抗b因子抗体およびそれらの使用 Pending JP2011503094A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US264807P 2007-11-08 2007-11-08
PCT/US2008/082621 WO2009061910A1 (en) 2007-11-08 2008-11-06 Anti-factor b antibodies and their uses

Publications (2)

Publication Number Publication Date
JP2011503094A JP2011503094A (ja) 2011-01-27
JP2011503094A5 true JP2011503094A5 (https=) 2012-11-15

Family

ID=40344464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010533241A Pending JP2011503094A (ja) 2007-11-08 2008-11-06 抗b因子抗体およびそれらの使用

Country Status (15)

Country Link
US (4) US8158762B2 (https=)
EP (1) EP2209807A1 (https=)
JP (1) JP2011503094A (https=)
KR (1) KR20100105587A (https=)
CN (1) CN101918444A (https=)
AR (1) AR069233A1 (https=)
AU (1) AU2008323939A1 (https=)
BR (1) BRPI0820343A2 (https=)
CA (1) CA2704973A1 (https=)
CL (1) CL2008003313A1 (https=)
IL (1) IL205577A0 (https=)
MX (1) MX2010005115A (https=)
PE (1) PE20091022A1 (https=)
TW (1) TW200927170A (https=)
WO (1) WO2009061910A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
TWI407953B (zh) * 2011-03-24 2013-09-11 Univ Kaohsiung Medical 用於調節補體因子b(cfb)表現的醫藥組合物
EP2855529A4 (en) * 2012-05-24 2015-12-09 Alexion Pharma Inc HUMANIZED ANTI-FACTOR B ANTIBODIES
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
JP6967528B2 (ja) * 2016-04-04 2021-11-17 バイオベラティブ ユーエスエー インコーポレイテッド 抗補体Bb因子抗体及びその使用
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
KR20230004686A (ko) 2020-04-20 2023-01-06 젠자임 코포레이션 인간화 항-보체 인자 Bb 항체 및 그의 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
ES2432112T3 (es) * 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
EP3299027A1 (en) * 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
KR101584468B1 (ko) * 2006-03-08 2016-01-13 아케믹스 엘엘씨 안질환의 치료에 유용한 보체 결합 앱타머 및 항-c5 제제
CA2678774A1 (en) 2007-03-01 2008-09-04 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation

Similar Documents

Publication Publication Date Title
JP2010528047A5 (https=)
RU2014113046A (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом
JP2020062036A5 (https=)
WO2008154251A4 (en) C3b antibodies and methods for the prevention and treatment of complement- associated disorders
JP2011504872A5 (https=)
JP2020079246A5 (https=)
JP2016504416A5 (https=)
JP2017536341A5 (https=)
JP2011503094A5 (https=)
JP2015503909A5 (https=)
JP2017536414A5 (https=)
HRP20211641T1 (hr) Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
JP2017535285A5 (https=)
JP2021520195A5 (https=)
RU2017102514A (ru) Гуманизированные анти-тау-антитела
JP2018510617A5 (https=)
JP2015509948A5 (https=)
JP2014532072A5 (https=)
JP2012525829A5 (https=)
RU2008138399A (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕ ТИРОЗИН ФОСФАТАЗУ БЕТА ЧЕЛОВЕКА (НРТРβ), И ИХ ИСПОЛЬЗОВАНИЕ
JP2019505527A5 (https=)
JP2016513682A5 (https=)
JP2013528607A5 (https=)
JP2010520290A5 (https=)